ClinicalTrials.gov
public full text
Public Domain
Body Composition Analysis and Time to Emergence From Remimazolam
Remimazolam is a novel general anesthetic drug. The time to emergence from remimazolam-based general anesthesia is variable among patients, but little is known about the risk factors for delayed emergence. We believe that information from body composition analysis may be helpful in understanding which patients are more likely to show delayed emergence from remimazolam.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- The Study of Ciprofol for the Suppression of Cardiovascular Responses to Tracheal Intubation#875085
- The Effect of Wavelet Index in Monitoring the Sedation Depth of Remimazolam Besylate#915162
- Effect of Body Mass on Filgrastim Pharmacokinetics#849330
- Anesthesia on Gut Microbiota and Metabolomics#460114
- The Median Effective Dose of Remimazolam for Duodenoscopy Insertion During ERCP With Alfentanil 10µg/kg#852356
Record · ID 993964
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive